source
- Turn Therapeutics' eczema drug shows rapid response in mid-stage dataCalifornia biotech Turn Therapeutics shared Phase 2 data for its topical atopic dermatitis treatment that show patients experienced symptom improvement faster than usual. In an interim analysis of…Endpoints · 1mo ago↗ source
- Servier signs $1.55B upfront deal for Edgewise's muscular dystrophy assetsServier will pick up the muscular dystrophy business from Edgewise Therapeutics for $1.55 billion upfront, giving the French pharma company access to an experimental neuromuscular medicine that cou…Endpoints · 1mo ago↗ source
- #ASCO26: AstraZeneca's triplet combo succeeds in liver cancer subgroupCHICAGO — AstraZeneca on Monday reported data from a new study showing the combination of a targeted treatment and two immunotherapies can benefit patients with certain kinds of liver cancer. Indiv…